Catch up with our Natural Resources online IR event which featured guest speakers from Orosur Mining, Rainbow Rare Earths, Savannah Resources, and Goldplat. View the presentation here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 134.00
Bid: 133.00
Ask: 135.00
Change: -10.50 (-7.27%)
Spread: 2.00 (1.50%)
Open: 145.00
High: 136.00
Low: 127.00
Yest. Close: 144.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: Avacta Group Enters License Agreement With Point Biopharma

IN BRIEF: Avacta Group Enters License Agreement With Point Biopharma

7 Jan 21 13:51

Avacta enters licence agreement with Point Biopharma

(Sharecast News) - Cancer therapy and diagnostics developer Avacta Group has entered into a licence agreement with Point Biopharma, it announced on Thursday, to provide access to its 'preCISION' technology for the development of tumour-activated radiopharmaceuticals.

7 Jan 21 08:58

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

23 Dec 20 19:50

Avacta submits clinical trial application for 'AVA6000' prodrug

(Sharecast News) - Cancer therapy developer Avacta Group has submitted a clinical trial application in the UK for a phase 1 first-in-human open label dose-escalation and expansion study of its lead 'preCISION' prodrug, 'AVA6000', in patients with locally-advanced or metastatic selected solid tumours, it announced on Wednesday.

23 Dec 20 08:56

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

21 Dec 20 18:10

Avacta enters 'Affimer' licensing deal with Astrea Bioseparations

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a licensing agreement with Astrea Bioseparations, it announced on Monday, for the use of the 'Affimer' platform in affinity purification applications.

21 Dec 20 09:49

Avacta reports 'significant progress' on Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group announced "significant progress" in the development of a scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions on Monday.

23 Nov 20 15:20

UK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares

UK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares

22 Oct 20 15:53

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

1 Oct 20 06:40

UK's Integumen unveils prototype COVID-19 breath test

LONDON, Sept 24 (Reuters) - Integumen, a British company that developed a system to detect the COVID-19 virus in waste water, said the same technology could be deployed in a personalised breath test that could become an effective tool in fighting...

24 Sep 20 15:43

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

21 Sep 20 16:08

IN BRIEF: Avacta To Launch SARS-CoV-2 Elisa Laboratory Test

IN BRIEF: Avacta To Launch SARS-CoV-2 Elisa Laboratory Test

7 Sep 20 14:28

Avacta launching Covid-19 laboratory test

(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that it will launch an 'ELISA' laboratory test for the SARS-CoV-2 spike protein, to support global research efforts into the coronavirus that causes Covid-19.

7 Sep 20 12:55

IN BRIEF: Avacta Expands Covid-19 Saliva Test Manufacturing Capacity

IN BRIEF: Avacta Expands Covid-19 Saliva Test Manufacturing Capacity

2 Sep 20 15:50

Avacta signs Covid-19 test manufacturing deal with Abingdon

(Sharecast News) - Biotherapeutics company Avacta Group has entered into an agreement with Abingdon Health for the manufacture of its saliva-based rapid SARS-CoV-2 antigen test, it announced on Wednesday, as part of its ongoing expansion of manufacturing capacity.

2 Sep 20 13:37

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.